FierceBiotech

Spero Therapeutics is pivoting from antibiotics to immune and inflammation indications by licensing a CD40L antibody from Innovent Biologics in a deal worth up to $1.1 billion. fiercebiotech.com/biotech/spero-…

Avere Therapeutics has burst onto the scene by securing a public listing via a reverse merger with NextCure, while stocking its pipeline with an IL-23 drug from Hansoh Pharmaceutical. fiercebiotech.com/biotech/avere-…

Biogen bolsters hopes for Alzheimer's pivotal push as anti-tau oligo slows cognitive decline fiercebiotech.com/biotech/aaic-b… #AAIC

Summit sells failed antibiotic to OpenAI-backed startup in $105M deal fiercebiotech.com/biotech/summit…

Apnimed dreams of IPO to fund launch of sleep apnea pill on FDA's desk fiercebiotech.com/biotech/apnime…

Biotechs forced to learn new patent tricks to protect pipelines fiercebiotech.com/biotech/how-di…

A new Fierce Biotech special report examines the forces shaping emerging biotech hubs. fiercebiotech.com/special-report…

🎧 New today on The Top Line: A $10B deal, China trial scrutiny and highlights from ADA 2026 fiercepharma.com/pharma/10b-dea…

GSK sees phase 3 win for Hansoh-partnered ADC in China as validating its ‘priority asset’ $GSK fiercebiotech.com/biotech/gsk-se…

Roche has halted development on two of its Huntington’s disease prospects, delivering another blow to a patient community that has long awaited new medicines. $ROCH.NE fiercebiotech.com/biotech/roche-…

The FDA has paused a controversial policy of releasing letters describing its rationale for rejecting drugs, Fierce Biotech has learned, following a citizen’s petition from an unnamed pharma company in April. fiercebiotech.com/biotech/fda-ha…

GSK has walked away from a $2.2 billion biobucks neurodegenerative disease pact with Alector that has seen both drugs involved flunk clinical trials. fiercebiotech.com/biotech/gsk-cu… $GSK

Prime Medicine has come out ahead in its patent dispute with fellow gene editing biotech Beam Therapeutics. fiercebiotech.com/biotech/prime-…

AstraZeneca pens $2.1B Sino deal for challenger to Merck’s COPD drug Ohtuvayre fiercebiotech.com/biotech/astraz…

Fierce Biotech Layoff Tracker: Novartis loses 322 US staffers; BioCryst ends internal programs fiercebiotech.com/biotech/fierce…

Precision immunology company Scipher Medicine will absorb Chemomab Therapeutics after having identified the Israeli biotech’s rheumatoid arthritis drug as the ideal fit for its own expertise. fiercebiotech.com/biotech/sciphe…

Satellos’ ‘intriguing’ Duchenne data raise hopes ahead of key readout fiercebiotech.com/biotech/satell…

Endevica spinout Kalohexis submits confidential IPO filing to develop obesity challenger to GLP-1s fiercebiotech.com/biotech/metabo…

As US lawmakers increase scrutiny of Chinese trials, industry fears ‘huge distraction and expense’ fiercebiotech.com/biotech/us-law…

Boehringer Ingelheim has landed an exclusive license to Prime Vector Technologies’ viral vector platform for developing next-generation cancer vaccines. fiercebiotech.com/biotech/boehri…